期刊文献+

免疫凝集法检测糖化血红蛋白的应用评价 被引量:4

下载PDF
导出
摘要 目的了解免疫凝集法检测糖化血红蛋白试剂盒测定结果的准确性、可靠性,并对其进行方法学评价,为临床在分析不同方法检测糖化血红蛋白结果时提供参考。方法参照美国临床实验室标准化委员会的方法学评价方案,与美国BIO-RADVARIANTⅡ糖化血红蛋白分析仪检测HbA1c(%)的结果进行对比,同时监测放置时间对其结果的影响。结果免疫凝集法线性良好,稀释变异可接受,线性范围为0~5.2g/L,最低可检出限为0.074g/L。日间CV=4.33%,批内CV=3.02%,批间CV=3.39%,总CV=4.51%。血浆中高浓度胆红素、三酰甘油和尿素干扰HbA1c的检测。全血标本4℃条件下放置2周后结果稳定;溶血标本4℃条件下放置6个月结果稳定。结论免疫凝集法检测HbA1c的线性范围、稀释变异均符合临床检测要求,最低可检出限度为0.074g/L,不精密度小于5%。与美国BIO-RAD VARIANTⅡ糖化血红蛋白分析仪检测结果比较,差异无统计学意义。可采用在4℃保存的溶血标本作为室内质控品。
出处 《国际检验医学杂志》 CAS 2011年第19期2240-2241,共2页 International Journal of Laboratory Medicine
  • 相关文献

参考文献7

  • 1Zimmet P, Me Carty D. The NIDDM epidemic: global estimates and projection : a look into the crystal ball[J]. IDF Bulletin, 1995, 40(8) :8-16.
  • 2King H, Aubert RE, Herman WH. Global burden of diabetes, 1995- 2025 :prevalence,numerical estimates,and projeetion[J].Di abeles Care,1998,21(12):1414- 1431.
  • 3David B. Sacks G,David E, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabe- tes mellitus[J]. Clinical Chemistry,2002,48(3) :436- 472.
  • 4杨昌国,许叶,张抗.线性评价和干扰试验中NCCLS评价方案的应用[J].临床检验杂志,1999,17(3):184-186. 被引量:165
  • 5杨昌国,许叶,张抗.精密度评价和方法比较中NCCLS评价方案的应用[J].临床检验杂志,1999,17(1):47-49. 被引量:184
  • 6Passey RB. Quality control for the clinical chemistry laboratory [J]. Cvmosby Company,1996,28(3) :385-391.
  • 7David M,Nathan,Rury R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and ad- j ustment of therapy[J]. Diabetes Care, 2008,31 (3) : 173-175.

共引文献264

同被引文献42

  • 1邱文升.对糖化血红蛋白及其测定方法基本概念的认识[J].中国糖尿病杂志,1995,3(3):169-172. 被引量:15
  • 2无,龚兰生,许玉韵,张维忠,刘望彭,王新房,王宏宇,张瑞岩,郭远,李运田,马志敏,芦娜,倪永斌,王敏,杨娅,何建国,高旭光,丁康,沈晨阳,陈生龙,史旭波,陶军.中国血管病变早期检测技术应用指南(第一次报告)[J].中国民康医学,2006,18(9):323-331. 被引量:94
  • 3李岚岚,侯小洪,李霞,涂干卿.金标定量法检测糖化血红蛋白的方法学评价[J].国际检验医学杂志,2006,27(10):890-891. 被引量:4
  • 4陈文彬,潘详林.诊断学[M].北京:人民卫生出版社,2008:52-54.
  • 5张阳.糖化血红蛋白检测方法及临床应用[J].现代医药卫生,2007,23(15):2286-2287. 被引量:10
  • 6HIRSCH AT,HASKAL ZJ,HERTZER NR,et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease ( lower extremity, renal, mesenteric, and abdominal aortic ): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AI-IA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease ) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation ; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter- Society Consensus ; and Vascular Disease Foundation [ J ]. J Am Coll Cardiol,2006,47 (6) : 1239 - 1312.
  • 7SAHLI D, SVENSSON M, LIDGREN J, et al. Evaluation of simple non - invasive techniques for assessment of lower extremity arterial disease [ J ]. Clin Physiol Funct Imaging,2005,25 (5) : 129 - 134.
  • 8HAFFNER SM, MIETTINEN H, STERN MP. The homeostasis model in the san antonio heart study[ J]. Diabetes Care, 1997,20 (7) :1087.
  • 9Little RRtRohlfing CL. Hanson S, et al. Effects of hemo-globin( Hb) E and HbD traits on measurements of glycat-ed Hb(HbAlc) by 23 methods[J]. Clin Chem, 2008, 54(8):1277-1282.
  • 10Kaiser P, Akerboom T,Ohlendorf R,et al. Liquid chroma-tography-isotope dilution-mass spectrometry as a new ba-sis for the reference measurement procedure for hemoglo-bin Ale determination[J]. Clin Chem, 2010, 56 ( 5) : 750-754.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部